ProPath Names Cary J. Buresh, M.D., as Director of Immunohistochemistry Division

DALLAS--(BUSINESS WIRE)--The ProPath Immunohistochemistry (IHC) division is one of the most sophisticated specialty laboratories in the country. The methods employed involve the use of antibodies or small fragments of DNA as probes to analyze cell samples or tissue specimens and address numerous common problems in diagnostic pathology. After the recent retirement of longtime IHC Director, Rodney T. Miller, M.D., ProPath has selected Cary J. Buresh, M.D. as the perfect person to lead this vital division into the new decade. Dr. Buresh has been a member of the IHC Laboratory and Consultation Services team since 2002 and worked closely with Dr. Miller on thousands of cases.

“While it’s difficult to replace someone of Dr. Miller’s stature, we are fortunate to have the depth of talent and experience that we have,” said Cory A. Roberts, M.D., President, Chairman and CEO of ProPath. “I am thrilled that Dr. Buresh agreed to step in and he will do a great job taking over the Director position. This transition has been several months in the making and that type of planning and overlap is invaluable in a smooth succession plan.”

“Having been here for 18 years working with Dr. Miller, I am fortunate to have learned directly from the best,” said Dr. Buresh. “I am anxious to continue in the tradition of innovation and excellence that he started. With our IHC group of Drs. Oliai, El-Zayaty and Liu, we have a great team that will carry on the ProPath reputation.”

Dr. Buresh hails from Nebraska, where he attended the University of Nebraska Medical Center, ending his time there as Chief Resident. He completed the oncologic surgical pathology fellowship at the renowned Memorial Sloan Kettering Cancer Center in New York. There he learned from such pathology giants as Drs. Juan Rosai and James Woodruff.

Dr. Buresh has published numerous papers during his career, on topics ranging from soft tissue tumor diagnostics to cytogenetics. In addition to his expertise with various tumors, he also has special expertise in breast and hepatic pathology.

Other members of the consult team include Dr. Robert Oliai, who has sub-specialty expertise in genitourinary pathology and sub-specialty board certification in cytopathology. Dr. Chad El-Zayaty hails from the University of Chicago. After completing a surgical pathology fellowship there, he published several papers and wrote a book chapter on tumors for McGraw-Hill’s Dermatopathology, 3rd Edition. Dr. Chengbao Liu completed the prestigious Memorial Sloan Kettering oncologic surgical pathology fellowship and a gynecologic pathology fellowship under Dr. Brigitte M. Ronnett at The Johns Hopkins Hospital in Baltimore, Collectively, the team has over 50 years of post-training experience. With Dr. Buresh at the helm, this powerhouse team will continue to uphold ProPath’s IHC lab’s standard of excellence.

About ProPath:

ProPath is the largest, nationwide, 100 percent physician-owned pathology practice in the United States. Led by a team of world-class physicians and scientists, ProPath routinely diagnoses cases from 45 states and several foreign countries. Its 500 employees reside in 10 states and staff lab facilities in two states. For 54 years, ProPath’s mission has been to provide patient-centered, high quality and effective medical diagnostics, prognostics and research that creates better patient outcomes.